KSR2変異は,肥満,インスリン抵抗性,細胞燃料酸化障害と関連しています
Cell
|November 12, 2013
まとめ
Ras 2 (KSR2) のキナーゼ抑制剤の珍しい変種は,エネルギーバランスと代謝を乱すことで重度の肥満を引き起こす. メトホルミンは,変異媒介者の細胞機能を改善することで役立つ可能性があります.
科学分野:
- 遺伝学 遺伝学とは
- メタボリズムは
- 分子生物学は分子生物学である.
背景:
- Ras 2 (KSR2) のキナーゼ抑制剤は,細胞信号伝達に関与する細胞内支架タンパク質です.
- マウスにおけるKsr2の欠失は肥満を誘発し,エネルギーホメオスタシスにおけるKsr2の役割を示している.
研究 の 目的:
- 人間の肥満におけるKSR2の役割を調査する.
- 早期発症の重度の肥満に関連するKSR2の遺伝子変異を特定する.
主な方法:
- 早期発症重度の肥満患者2,101人,対照患者1,536人のKSR2の配列解析.
- KSR2の変種が信号伝達経路と基板酸化に与える影響を評価するために,感染した細胞での機能研究.
- 代謝現象型のための変異媒体の臨床評価.
主要な成果:
- 重度の肥満の個体において,複数のまれなKSR2変異が特定されました.
- これらの変種は,Raf-MEK-ERK経路を混乱させ,細胞脂肪酸とグルコースの酸化を損なう.
- 細胞モデルではメトホルミンによって効果が改善された.
- 変異媒介者は,過食症,低心拍数,基礎代謝率低下,重度のインスリン抵抗性を示した.
結論:
- KSR2は,ヒトにおけるエネルギー摂取,消費,および基板利用の重要な調節因子である.
- KSR2機能障害は重度の肥満とインスリン抵抗性につながる.
- KSR2媒介経路をターゲットにすることは,肥満と2型糖尿病に対する潜在的な治療戦略を提供します.
関連する概念動画
Type II Diabetes I: Introduction
57
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
57
Electron Transport Chain: Complex I and II
11.9K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
11.9K
The Ras Gene
5.7K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
5.7K
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
Type II Diabetes II: Pathophysiology
36
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
36
PI3K/mTOR/AKT Signaling Pathway
5.2K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.2K


